GI Cell and HK Inno.N begin joint research on next-generation CAR-NK cell therapy

The companies plan to advance the development of numerous CAR-NK therapies by harnessing GI Cell's outstanding research competency and HK inno.N's extensive experience in development and commercialization of anticancer therapies.

 

As part of this agreement, the companies may open up a discussion on further developments, including clinical development and commercialization, if they succeed in discovering CAR-NK cell product candidates and producing non-clinical samples.

 

GI Cell, pioneering novel technology for large-scale immune cell manufacturing, expects to demonstrate its technology on scalable culture under this research agreement.

 

In February, GI Cell set a new world record in culturing highly active natural killer (NK) cells with 200 liters. The company's manufacturing technology obtained a patent registration decision in Taiwan in July, following the corresponding patent registration in Korea at the beginning of the year.

 

GI Cell and HK inno.N will co-develop CAR-NK programmes with the aim of initiating the clinical phase of CAR-NK cell therapy products by 2024.